Antiplatelet Agents

PreclinicalSmall molecule

SSeoul National University Hospital

Antiplatelet Agents is one of 103 small molecule programs targeting Heart Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart DiseaseActive, not recruiting

StrokeActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Stroke, AcuteRecruiting

Heart DiseasePreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

Stroke, AcutePreclinical

Recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Zometa

Pfizer

Preclinical

1 2

Savella

AbbVie

Preclinical

1 3

Proamatine

Repatha

Zantac 150

1 6

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Inderal

Mylan Pharmaceuticals Inc

Coumadin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Chronic Coronary Syndrome

NCT06198673

Q4 2027

PreclinicalRecruiting

Stroke, Acute

NCT04261478

Q4 2028

Active, not recruiting

Stent Implantation

NCT05567536

Clinical

Trials by Indication[1]

Heart Disease1 trial

Study on the Registration of Coronary Heart Disease Patients Undergoing PCI

Completed·TThe Third Xiangya Hospital of Central South University··NCT02888652·1,500 enrolled

Antiplatelet1 trial

Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention

Completed·SSamsung Medical Center··NCT06281041·4,657 enrolled

Endothelial Function1 trial

Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone

Unknown status·AAlfa Wassermann Tunisia·Phase 3·NCT03370705·156 enrolled

Coronary Artery Ectasia1 trial

Coronary Artery Ectasia in Elective Coronary Angiography : Predictors, Outcomes and Management

Completed·—·N/A·NCT03896321·79 enrolled

Large Vessel Occlusion1 trial

Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window

Completed·XXuanwu Hospital, Beijing·Phase 4·NCT05752916·570 enrolled

6 more indications

Intracerebral Hemorrhage1 trial

Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage

Completed·—·N/A·NCT04820972·269 enrolled

Chronic Coronary Syndrome1 trial

A Prospective muLticEnter Registry in chrONic coronARy synDrOme

Not yet recruiting·UUniversity of Roma La Sapienza··NCT06198673·1,000 enrolled

Cardiovascular1 trial

Reducing Total Cardiovascular Risk in an Urban Community

Completed·JJohns Hopkins University·Phase 4·NCT00241904·525 enrolled

Stent Implantation1 trial

Long Term Follow-up of Comparison of Clopidogrel vs. Aspirin Monotherapy After Drug-eluting Stent Implantation

Active, not recruiting·SSeoul National University Hospital··NCT05567536·5,530 enrolled

Antithrombotic1 trial

Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

Unknown status·CChina National Center for Cardiovascular Diseases··NCT05006677·480 enrolled

Stroke, Acute1 trial

A Multi-centre, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) Controlled Trial Comparing Cervical Internal Carotid Artery Stenting to no Stenting During Thrombectomy for Tandem Occlusion Stroke

Recruiting·CCentre hospitalier de l'Université de Montréal (CHUM)·Preclinical·NCT04261478·458 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Antiplatelet Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiplatelet Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiplatelet Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul National University Hospital

Antiplatelet Agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Trials by Indication[1]

Heart Disease1 trial

Antiplatelet1 trial

Endothelial Function1 trial

Coronary Artery Ectasia1 trial

Large Vessel Occlusion1 trial

Intracerebral Hemorrhage1 trial

Chronic Coronary Syndrome1 trial

Cardiovascular1 trial

Stent Implantation1 trial

Antithrombotic1 trial

Stroke, Acute1 trial

References

Drug Info

Quick Facts

Related News